Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Radboud University
• Treatments: Caffeine; Dipyridamole

Criteria

Inclusion Criteria:

• Male

• Age between 18-50yr.

Exclusion Criteria:

• cardiovascular disease

• hypertension (systole > 140 mmHg, diastole > 90 mmHg)

• hypercholesterolemia (random total cholesterol > 6.5 mmol/l)

• diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)

• asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists)

• participation in any clinical trial during the last 60 days prior to this study.

• administration of two doses of Annexin A5 (0,1mg; 450MBq) during the last 5 years prior to this study.